Zhengye Biotechnology (ZYBT) Competitors $5.56 -0.31 (-5.28%) As of 07/15/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock ZYBT vs. ARDX, PRAX, PROK, COLL, AKBA, AMPH, RCUS, DYN, SYRE, and VERVShould you be buying Zhengye Biotechnology stock or one of its competitors? The main competitors of Zhengye Biotechnology include Ardelyx (ARDX), Praxis Precision Medicines (PRAX), ProKidney (PROK), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Amphastar Pharmaceuticals (AMPH), Arcus Biosciences (RCUS), Dyne Therapeutics (DYN), Spyre Therapeutics (SYRE), and Verve Therapeutics (VERV). These companies are all part of the "pharmaceutical products" industry. Zhengye Biotechnology vs. Its Competitors Ardelyx Praxis Precision Medicines ProKidney Collegium Pharmaceutical Akebia Therapeutics Amphastar Pharmaceuticals Arcus Biosciences Dyne Therapeutics Spyre Therapeutics Verve Therapeutics Ardelyx (NASDAQ:ARDX) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership. Is ARDX or ZYBT more profitable? Zhengye Biotechnology has a net margin of 0.00% compared to Ardelyx's net margin of -14.86%. Zhengye Biotechnology's return on equity of 0.00% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Ardelyx-14.86% -34.45% -13.81% Zhengye Biotechnology N/A N/A N/A Do insiders and institutionals have more ownership in ARDX or ZYBT? 58.9% of Ardelyx shares are held by institutional investors. 4.8% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation and earnings, ARDX or ZYBT? Zhengye Biotechnology has lower revenue, but higher earnings than Ardelyx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArdelyx$333.61M3.23-$39.14M-$0.22-20.45Zhengye Biotechnology$25.53M10.27N/AN/AN/A Does the media refer more to ARDX or ZYBT? In the previous week, Ardelyx had 6 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 7 mentions for Ardelyx and 1 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 1.89 beat Ardelyx's score of 0.61 indicating that Zhengye Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Ardelyx Positive Zhengye Biotechnology Very Positive Do analysts rate ARDX or ZYBT? Ardelyx presently has a consensus price target of $10.89, indicating a potential upside of 141.98%. Given Ardelyx's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ardelyx is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardelyx 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryArdelyx beats Zhengye Biotechnology on 8 of the 13 factors compared between the two stocks. Get Zhengye Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYBT vs. The Competition Export to ExcelMetricZhengye BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$276.87M$2.96B$5.62B$9.29BDividend YieldN/A2.43%4.25%4.03%P/E RatioN/A20.2228.5719.58Price / Sales10.27290.24423.3293.40Price / CashN/A43.1536.0257.93Price / BookN/A7.568.135.54Net IncomeN/A-$55.11M$3.24B$257.73M7 Day Performance-8.70%3.81%0.16%-0.08%1 Month Performance-22.56%11.60%5.95%8.09%1 Year PerformanceN/A-2.11%26.09%13.02% Zhengye Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYBTZhengye BiotechnologyN/A$5.56-5.3%N/AN/A$276.87M$25.53M0.00278Positive NewsGap UpARDXArdelyx4.0655 of 5 stars$4.50-2.4%$10.89+142.0%-24.4%$1.10B$333.61M-20.4590PRAXPraxis Precision Medicines2.2504 of 5 stars$51.89-3.2%$94.11+81.4%+1.8%$1.09B$8.55M-4.84110PROKProKidney3.5224 of 5 stars$3.37-8.7%$6.25+85.5%+41.0%$1.08B$80K-5.623Trending NewsAnalyst ForecastGap UpHigh Trading VolumeCOLLCollegium Pharmaceutical4.2933 of 5 stars$32.00-2.5%$43.75+36.7%+0.7%$1.05B$631.45M26.23210Buyback AnnouncementAKBAAkebia Therapeutics3.6441 of 5 stars$3.88-2.3%$6.75+74.0%+196.2%$1.04B$160.18M-18.48430AMPHAmphastar Pharmaceuticals4.2845 of 5 stars$21.18-3.5%$32.33+52.7%-45.4%$1.03B$731.97M7.672,028RCUSArcus Biosciences2.3011 of 5 stars$9.03-6.4%$21.29+135.7%-41.5%$1.02B$258M-2.16500DYNDyne Therapeutics4.0159 of 5 stars$8.28-7.1%$40.63+390.6%-80.9%$1.01BN/A-2.31100Analyst ForecastInsider TradeSYRESpyre Therapeutics1.8977 of 5 stars$15.31-6.7%$53.40+248.8%-46.8%$989.12M$890K-4.0673Positive NewsGap UpVERVVerve Therapeutics3.0219 of 5 stars$11.02-0.1%$14.57+32.2%+53.9%$983.25M$32.33M-5.22110 Related Companies and Tools Related Companies ARDX Alternatives PRAX Alternatives PROK Alternatives COLL Alternatives AKBA Alternatives AMPH Alternatives RCUS Alternatives DYN Alternatives SYRE Alternatives VERV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZYBT) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zhengye Biotechnology Holding Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zhengye Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
